DK1224163T3 - Anvendelse af carbonylaminoderivater mod CNS-lidelser - Google Patents

Anvendelse af carbonylaminoderivater mod CNS-lidelser

Info

Publication number
DK1224163T3
DK1224163T3 DK00969435T DK00969435T DK1224163T3 DK 1224163 T3 DK1224163 T3 DK 1224163T3 DK 00969435 T DK00969435 T DK 00969435T DK 00969435 T DK00969435 T DK 00969435T DK 1224163 T3 DK1224163 T3 DK 1224163T3
Authority
DK
Denmark
Prior art keywords
cns disorders
derivatives against
against cns
carbonylamino derivatives
carbonylamino
Prior art date
Application number
DK00969435T
Other languages
Danish (da)
English (en)
Inventor
Vincent Mutel
Eric Vieira
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1224163T3 publication Critical patent/DK1224163T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00969435T 1999-10-12 2000-10-06 Anvendelse af carbonylaminoderivater mod CNS-lidelser DK1224163T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99120327 1999-10-12
EP00969435A EP1224163B1 (en) 1999-10-12 2000-10-06 Use of carbonylamino derivatives against cns disorders
PCT/EP2000/009781 WO2001027070A1 (en) 1999-10-12 2000-10-06 Use of carbonylamino derivatives against cns disorders

Publications (1)

Publication Number Publication Date
DK1224163T3 true DK1224163T3 (da) 2005-06-27

Family

ID=8239189

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00969435T DK1224163T3 (da) 1999-10-12 2000-10-06 Anvendelse af carbonylaminoderivater mod CNS-lidelser

Country Status (18)

Country Link
US (1) US6548522B1 (es)
EP (1) EP1224163B1 (es)
JP (1) JP4098523B2 (es)
KR (1) KR100468253B1 (es)
CN (1) CN1184964C (es)
AR (1) AR025990A1 (es)
AT (1) ATE292107T1 (es)
AU (1) AU775656B2 (es)
BR (1) BR0014712A (es)
CA (1) CA2388470C (es)
DE (1) DE60019145T2 (es)
DK (1) DK1224163T3 (es)
ES (1) ES2238316T3 (es)
MX (1) MXPA02003673A (es)
PT (1) PT1224163E (es)
TR (1) TR200200969T2 (es)
WO (1) WO2001027070A1 (es)
ZA (1) ZA200202437B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399641B1 (en) * 2000-07-13 2002-06-04 Hoffmann-La Roche Inc. 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists
WO2003004010A1 (en) * 2001-07-06 2003-01-16 Poseidon Pharmaceuticals A/S Carbonylamino derivatives useful for obtaining immune regulation
AU2003201273A1 (en) 2002-01-04 2003-07-30 Poseidon Pharmaceuticals A/S Potassium channel modulators
CN101821256A (zh) 2007-08-02 2010-09-01 瑞蔻达蒂爱尔兰有限公司 作为mGlu5拮抗剂的新型杂环化合物
EP2322164A3 (en) 2007-08-24 2011-12-07 NeuroSearch A/S Carbonylamino derivatives useful for the treatment of inflammatory bowel disease
US20100317630A1 (en) 2009-02-04 2010-12-16 Recordati Ireland Limited Novel heterocyclic compounds as mglu5 antagonists
WO2011029633A1 (en) 2009-09-14 2011-03-17 Recordati Ireland Limited Heterocyclic mglu5 antagonists
CN101786982A (zh) * 2010-03-30 2010-07-28 华东师范大学 一种合成2-吡啶基苯乙腈的方法
KR101862626B1 (ko) 2010-07-09 2018-05-31 레코르다티 아일랜드 리미티드 Mglu5 대항체로서의 신 스피로헤테로사이클릭 화합물
JP5886869B2 (ja) 2010-12-17 2016-03-16 ローズ テクノロジーズ メチルフェニデート塩酸塩の低温合成
CN110372530B (zh) * 2019-08-06 2021-07-30 郑州大学 一种含α取代苯基结构的化合物及其制备方法和消杀剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129434C (es) 1966-03-12
EP0474589A1 (de) 1990-08-02 1992-03-11 Ciba-Geigy Ag Orthophenolacetamide
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
JP3197822B2 (ja) 1996-01-31 2001-08-13 株式会社スリオンテック 可逆性感熱記録組成物とそれを用いた書き替え可能な可逆性感熱記録シートおよびカード
JP2002511835A (ja) 1996-06-07 2002-04-16 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド 神経障害および神経病の治療に有用な受容体作動性カルシウムチャネル上の新規部位で活性な化合物
AU763245B2 (en) 1997-12-10 2003-07-17 Nps Pharmaceuticals, Inc. Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides

Also Published As

Publication number Publication date
ES2238316T3 (es) 2005-09-01
CN1378528A (zh) 2002-11-06
ZA200202437B (en) 2003-09-23
DE60019145D1 (de) 2005-05-04
KR100468253B1 (ko) 2005-01-27
TR200200969T2 (tr) 2002-07-22
US6548522B1 (en) 2003-04-15
JP2003511436A (ja) 2003-03-25
MXPA02003673A (es) 2002-08-30
AU7915100A (en) 2001-04-23
CN1184964C (zh) 2005-01-19
WO2001027070A1 (en) 2001-04-19
PT1224163E (pt) 2005-06-30
BR0014712A (pt) 2002-06-18
EP1224163A1 (en) 2002-07-24
ATE292107T1 (de) 2005-04-15
EP1224163B1 (en) 2005-03-30
AR025990A1 (es) 2002-12-26
DE60019145T2 (de) 2006-01-26
CA2388470C (en) 2008-08-05
JP4098523B2 (ja) 2008-06-11
AU775656B2 (en) 2004-08-12
KR20020038947A (ko) 2002-05-24
CA2388470A1 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1438306T3 (da) Derivater af UK-2A
AR028567A1 (es) Nuevos derivados de fenil-propargileter
CY2009001I2 (el) Νεα μορφη κρυσταλλου του παραγωγου πυρρολιδυλοθειοκαρβαπενεμης
AR027938A1 (es) Compuestos uracilo y utilizacion de los mismos
NO20030406L (no) Ikke-steroidale antiinflammatoriske midler
NO20014047D0 (no) Monoamin reopptaksinhibitorer for behandling av CNS forstyrrelser
AR028596A1 (es) Nuevos derivados de fenilglicina
ATE502923T1 (de) Amid-verbindungen
EE200100135A (et) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
DK1224163T3 (da) Anvendelse af carbonylaminoderivater mod CNS-lidelser
EE200400104A (et) N-(3-butüün-1-üül)-N-hüdroksüuurea
NO20041968L (no) Anvendelse av cystationin
ID30023A (id) Kombinasi senyawa aktif fungisida
NO20026005L (no) Indolderivater nyttige for behandlingen av CNS-forstyrrelser
DK1102747T3 (da) Krystalformer af osenetant
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
NO20030127L (no) Indolderivater nyttige for behandling av CNS-forstyrrelser
EE200100381A (et) Morfolinobensamiidi uued soolad
NO20026029D0 (no) Indolderivater nyttige for behandlingen av CNS-forstyrrelser
EE200100017A (et) N-tert-butüülhüdroksüülamiini uued soolad
DE60214475D1 (de) Reinigungsband
DK1468686T3 (da) S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser
TR199902015A3 (tr) Aril-sikloheksilamin türevlerinin CNS bozukluklarina karsi kullanilmasi.
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner